recently, the value selection results of the 2021 financial leadership china "golden intelligence award" listed company were officially announced, and shanghai raas was awarded the excellent business practice award in the chinese pharmaceutical and biological industry.
the 2021 china pharmaceutical and biological industry excellent business practice award aims to recognize pharmaceutical and biological enterprises with outstanding commercial value. this award aims to objectively evaluate the concrete commercial value of a-share and hong kong listed pharmaceutical and biological enterprises by comprehensively measuring their differentiated advantages in production, operation, sales, as well as capital and development levels. the evaluation index system includes various data dimensions such as operational efficiency, operational health, capital return, and growth ability.
winning the 2021 china pharmaceutical and biological industry excellent business practice award proves the outstanding performance of shanghai raas in business practice in 2021. as a pharmaceutical and biological enterprise that has been deeply involved in the blood product industry for 33 years, shanghai raas continuously improves its commercial market development capabilities, strengthens its research and development innovation capabilities and efficiency, and advances its internationalization process. on the path of future development, shanghai raas will continue to focus on enhancing commercial value and steadily move forward on the path of high-quality development.